Table 1.
The association of three non-synonymous SNPs in BALF2 gene and the risk for NPC
| SNP | High-risk genotype | Discovery |
Validation |
Combined |
Odds ratio | 95% CI |
P value
conditional on SNPs |
Annotation | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 156 cases | 47 controls | P value | 483 cases | 605 controls | P value | 639 cases | 652 controls | P value | 163364 | 162476 | |||||
| 162215C>A | C | 96.15% | 65.96% | 3.22×10−04 | 95.03% | 74.71% | 9.92×10−16 | 95.31% | 74.08% | 1.42×10−18 | 7.60 | 4.97–11.62 | 7.78×10−05 | 1.94×10−01 | BALF2, V700L |
| 162476T>C | C | 93.59% | 61.70% | 5.09×10−03 | 94.00% | 65.12% | 1.94×10−23 | 93.90% | 64.88% | 9.69×10−25 | 8.69 | 5.79–13.03 | 1.10×10−06 | BALF2, I613V | |
| 163364C>T | T | 88.46% | 48.94% | 7.95×10−03 | 83.85% | 45.45% | 6.92×10−32 | 84.98% | 45.71% | 2.40×10−32 | 6.14 | 4.59–8.22 | 4.84×10−11 | BALF2, V317M | |
The association of three EBV SNPs with NPC risk was tested in discovery and validation samples and with a meta-analysis of the combined discovery and validation samples. Frequencies of high-risk genotypes in discovery, validation and combined analyses are indicated. Odds ratios conferred by high-risk genotypes and the 95% confidence intervals (CI) were estimated from the meta-analysis of the combined discovery and validation phases. Conditional regression analyses were performed in combined samples, and P values of SNP associations in conditional analyses are listed.